Business Wire

ReSound® Introduces the World’s Smartest Super Power Hearing Aid

Del

Today, GN ReSound announced the global launch of ReSound ENZO2™, bringing the renowned benefits of ReSound LiNX2™ to people with severe to profound hearing loss in need of a Super Power solution.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160301006081/en/

ReSound ENZO2 launches globally today. (Photo: Business Wire)

ReSound ENZO2 launches globally today. (Photo: Business Wire)

As the fourth generation of GN ReSound’s proprietary 2.4 GHz technology, ReSound ENZO2 is the only Smart Hearing aid for Super Power users that offers an exceptional hearing experience with greater audibility, better speech understanding, and improved spatial awareness, enabling people to live their life closer to normal than ever before.

The global launch of ReSound ENZO2 builds on the successful U.S. launch in the autumn of 2015. The hearing aid is already having a life-changing impact, as demonstrated by wearer James Raath: “I lost my hearing almost overnight, and of course that was a traumatic moment, as you can imagine… [Being fitted with ReSound ENZO 2 ] was completely life transforming. I began to see possibilities of getting back to work, to socialize as I hadn’t been able to do before.”

GN ReSound also introduce the new ReSound Micro Mic™ and ReSound Multi Mic™ microphones that connect to all ReSound Smart Hearing aids, including ReSound ENZO2 to further enhance the users sound experience in all relevant situations.

We are very excited to deliver the most advanced sound quality and introduce spatial sense to the Super Power users all over the world,” said GN ReSound CEO Anders Hedegaard. “Now, people with severe to profound hearing loss will benefit from our groundbreaking solutions that adapt to peoples’ lives instead of the other way around.

For hearing impaired children, GN ReSound also launches the new ReSound Up Smart™ 5, the only competitive solution combining Made for iPhone and ReSound’s innovative hearing technologies that effectively support speech and language development, educational skills, and social interaction.

With these introductions, ReSound Smart Hearing range now supports even the most challenging listening environments for users of all ages and hearing loss needs.

ReSound’s innovative Smart Hearing solutions are available through a global network of hearing professionals. Consumers can find more information about ReSound’s comprehensive portfolio of Smart Hearing aids by visiting www.resound.com.

About GN ReSound

GN ReSound is a leading international developer and manufacturer of innovative hearing healthcare solutions committed to let people hear more, do more and be more than they ever thought possible. The company has reinvented the hearing system with its revolutionary ReSound Smart™ Hearing aids that give impressive sound and personal freedom to hearing aid users through wireless smartphone and tablet connectivity. GN ReSound is part of GN Group comprising a unique portfolio of medical, professional & consumer sound solutions that make life sound better through its research, insights, and expertise in sound.

Contact information

GN ReSound
Louise Damgaard-Bochlas
+45 4575 1294
ldamgaard@gnresound.com
or
Jessica Larkin
+1-202-997-5582
jlarkin@mcbeestrategic.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia12.12.2017 00:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, which is investigational for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery). The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005311/en/ ALL is an aggressive type of blood cancer which can also involve the lymph nodes, spleen, liver, central

NTT Communications Strengthens its DDoS Protection Services with New Detection Solution11.12.2017 23:00Pressemelding

NTT Communications Corporation (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), announced that it is expanding its Distributed Denial of Service Protection Services (DPS) with the addition of DPS Detect. This new solution can help customers detect potential attacks directed to their networks and initiate mitigations faster. DDoS attacks can strike at any time, potentially crippling network infrastructure and severely degrading the performance and reachability of a website or other IP-accessible assets. The expanded DPS suite of services will enable Global IP Network customers around the world to easily customize the level of service and assistance that best fits their needs. “Network security is one of the top priorities for our company,” said Michael Wheeler, executive vice president of the NTT Communications

Interactive Brokers Launches Bitcoin Futures Trading at the Start of Trading December 10th, 201711.12.2017 16:28Pressemelding

Interactive Brokers Group, Inc. (NASDAQ GS:IBKR), a global electronic brokerage firm, began offering clients the ability to trade bitcoin futures at the start of trading on the Cboe Futures Exchange (CFE) on Sunday night, December 10th, 2017. In addition to offering bitcoin futures from the CFE, under the ticker symbol GXBT, the company plans to offer bitcoin futures from the Chicago Mercantile Exchange (CME) at the scheduled start of trading December 18th using the symbol BRR. IBKR was there at the start of trading and its systems operated normally. “Interactive Brokers was on the buy side of the low print of 14,710,” said Thomas Peterffy, founder, Chairman and CEO of Interactive Brokers. “A Registered Investment Advisor on the Interactive Brokers platform purchased two March contracts in the first minute of trading.” As of 9:15am ET on Monday, the company said that

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00Pressemelding

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice

Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47Pressemelding

The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i

Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18Pressemelding

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom